PSNL
Personalis, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +6.6% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 68 | +6 | 44.71M | $598.60M | +11 | −5 |
| Q1 2026 | 65 | +1 | 39.38M | $250.81M | +9 | −8 |
| Q4 2025 | 64 | +1 | 35.38M | $281.65M | +2 | −1 |
| Q3 2025 | 13 | 0 | 21.61M | $140.91M | n/a | n/a |
| Q2 2025 | 10 | -1 | 19.31M | $126.70M | n/a | −1 |
| Q1 2025 | 8 | -2 | 10.69M | $37.54M | n/a | −2 |
| Q4 2024 | 10 | 0 | 10.13M | $58.56M | n/a | n/a |
| Q3 2024 | 9 | +1 | 11.64M | $62.64M | +2 | −1 |
| Q2 2024 | 8 | n/a | 8.68M | $10.16M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management ✦ | 7.91M | +11.3% | $51.57M | 0.3% | ▲ Add | 6 | SEC ↗ |
| 2 | BlackRock ✦ (passive) | 5.64M | +8.5% | $36.80M | 0.0% | ▲ Add | 2 | SEC ↗ ×8 |
| 3 | The Vanguard Group ✦ (passive) | 3.01M | -4.2% | $19.60M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 4 | Geode Capital Management ✦ (passive) | 1.33M | -2.4% | $8.70M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 5 | Millennium Management ✦ | 1.21M | +11.0% | $7.89M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 6 | State Street Global Advisors ✦ (passive) | 926.35K | +34.7% | $6.04M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Goldman Sachs Group ✦ | 573.98K | n/a | $3.74M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 8 | Renaissance Technologies ✦ | 453.04K | -19.6% | $2.95M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 9 | Morgan Stanley ✦ | 342.06K | n/a | $2.23M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 10 | T. Rowe Price ✦ | 101.15K | 0.0% | $660,000 | 0.0% | Held | 6 | SEC ↗ |
| 11 | Two Sigma Investments ✦ | 56.76K | -0.2% | $370,062 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 12 | JPMorgan Chase ✦ | 49.67K | n/a | $323,822 | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 13 | Fidelity (FMR) ✦ | 2.35K | +1015.6% | $15,348 | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 140 holders, 84.04M shares, $493.33M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 4.00K sh · $64,848
Officer, Director · 7.46K sh · $120,985
Officer · 2.07K sh · $33,543
Officer · 2.93K sh · $47,541
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
12.5% of class · View original SEC filing ↗
2.0% of class · View original SEC filing ↗